research use only
Cat.No.S3723
| Related Targets | Adrenergic Receptor AChR COX Calcium Channel Histamine Receptor Dopamine Receptor GABA Receptor TRP Channel Cholinesterase (ChE) GluR |
|---|---|
| Other 5-HT Receptor Inhibitors | Puerarin WAY-100635 Maleate Serotonin (5-HT) HCl BRL-15572 Dihydrochloride SB269970 HCl Ketanserin RS-127445 Azacyclonol Nuciferine Flopropione |
|
In vitro |
DMSO
: 63 mg/mL
(199.49 mM)
Water : 63 mg/mL Ethanol : 1 mg/mL |
|
In vivo |
|||||
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.
| Molecular Weight | 315.8 | Formula | C17H17N3O.HCl |
Storage (From the date of receipt) | |
|---|---|---|---|---|---|
| CAS No. | 132907-72-3 | Download SDF | Storage of Stock Solutions |
|
|
| Synonyms | YM-060 | Smiles | CN1C=C(C2=CC=CC=C21)C(=O)C3CCC4=C(C3)NC=N4.Cl | ||
| Targets/IC50/Ki |
5-HT3 receptor
(in N1E-15 cells) 0.091 nM(Ki)
|
|---|---|
| In vitro |
Ramosetron Hydrochloride (YM-060) has very low afinity for nicotinic and GABA receptors. In vitro studies have also demonstrated that YM060 shows low afinity for 5-HT1-like, 5-HT2, alpha-1, atpha-2, beta-1, beta-2, histamine H1 and H2 receptors. YM-060 is expected not to have 5-HT4 receptor blocking activity.
|
| In vivo |
Ramosetron is known to potently inhibit stress-induced abnormal defecation in animals. Ramosetron has potent, rapid-onset, and long-lasting inhibitory effects on CFS-induced defecation in rats, without any influence on normal defecation. The inhibitory effect of ramosetron appeared immediately after dosing and lasted for many hours.
|
References |
|
(data from https://clinicaltrials.gov, updated on 2024-05-22)
| NCT Number | Recruitment | Conditions | Sponsor/Collaborators | Start Date | Phases |
|---|---|---|---|---|---|
| NCT01870895 | Completed | Diarrhea-predominant Irritable Bowel Syndrome |
Astellas Pharma Inc |
February 2013 | Phase 3 |
| NCT01394653 | Completed | Healthy|Plasma Concentration of YM060 |
Astellas Pharma Inc |
July 2011 | Phase 1 |
| NCT01392794 | Completed | Healthy|Plasma Concentration of YM060 |
Astellas Pharma Inc |
April 2011 | Phase 1 |
Tel: +1-832-582-8158 Ext:3
If you have any other enquiries, please leave a message.